CHEN Yi obtianed her Ph.D. degree from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2004. She was appointed as a staff member by the institute thereafter and conducted her postdoctoral research at University of Miami (U.S.A.) between 2006.12 and 2008.12. Her research interest concerns how histone methyltransferase singnaling is regulated, aiming at understanding the roles that histone methyltransferas play in tumorignesis and discovery on innovative anticancer drugs. In addition, she also focuses on development preclinical models for the application of precision oncology, such as patient-derived tumor xenografts and three-dimensional patient-derived tumor organoid cultures. She has published more than 80 research articles in SCI journals, such as Hepatology，Nat Commun，Haematologica , Theranostics，Clin Cancer Res, etc. She was granted some academic awards including Shanghai Science & Technology Award (the first prize, 2017), Avon Foundation-AACR International Scholar Award in Breast Cancer Research (2006), Servier Young Investigator in Pharmacology (2005).

EDUCATION

1990.9–1994.6 B.S. Zhejing University (Zhejiang Medical University)

1997.9–2001.3 M.S. Zhejing University

2001.9–2004.6 Ph.D. Shanghai Institute of Materia Medica

WORK EXPERIENCE

1994.7–2001.8 Assistant Research Fellow, Lecture, Zhejing University

2004.7–2010.8 Assistant Research Fellow, Associate Professor, Shanghai Institute of Materia Medica

2006.12–2008.12 Postdoctoral Fellow, Sylvester Cancer Center, University of Miami（AACR Scholorship）

2010.9 – Professor, Shanghai Institute of Materia Medica

2018.10– Principal Investigator, Shanghai Institute of Materia Medica

1.Discovery innovative anticancer drugs targeting histone modification enzymes, such as HDAC, EZH2, G9a, etc.

2.Development preclinical models such PDX, PDO for the application of precision oncology